Your partners in health.
Developing new life changing medicines.
WATER SOLUBLE SILDENAFIL CRYSTALS
VILYA'S technology allows us to deliver the drug any way we would like. Our Sildenafil is available as a pill, chewable, liquid, gel or intectable.
Semaglutide
Villya's 100% watersoluble Semaglutide with digestive protection pill.
HPLC Data
Above is our HPLC data of Semaglutide in Gastric Juice (stomach acid) upto 4 hours!
NMR
True water solubility is something you can measure. On the left regular Semaglutide in water on NMR maching, NO drug peaks. On the right Villya's Semaglutide WITH drug peaks in water.
Carbohydrate Loading
Villya used a safe carbohydrate to load Semaglutide that is not harmful and will not disrupt your guts microbiome. On the right is an industry standard to loading peptides SNAC.
BREAKTHROUGH GASTRIC STABILITY
Tested In Simulated Stomach Acid
To evaluate the durability of our semaglutide formulation, Villya conducted analytical testing using simulated gastric fluid.
Results
• Semaglutide remained structurally intact after four hours of exposure
• HPLC analysis demonstrated preservation of molecular integrity
• Chromatographic profiles remained stable throughout testing
• Minimal degradation observed during prolonged gastric exposure
These findings support the potential for robust oral peptide delivery under real-world physiological conditions.
The Future of Oral Peptide Medicines Starts Here
Transforming Injectable Medicines Into Oral Therapies
Villya Pharmaceuticals has developed a breakthrough patented technology designed to protect, stabilize, and enhance the solubility of peptide therapeutics, including semaglutide.
Built upon Villya's proprietary intellectual property portfolio, including Patent Application WO2025064695A1, our technology addresses one of the greatest challenges in pharmaceuticals.
THE VILLYA SOLUTION
A Molecular Shield For Peptide Therapeutics
Villya's patented technology is designed to create a protective molecular environment around semaglutide and other peptide therapeutics.
Our platform technology is engineered to:
✅ Improve water solubility
✅ Enhance molecular stability
✅ Protect peptides under acidic gastric conditions
✅ Maintain structural integrity
✅ Enable next-generation oral formulations
Rather than relying solely on absorption enhancers, Villya focuses on protecting the active pharmaceutical ingredient itself.
ORAL INSULIN REIMAGINED
A New Vision for Diabetes Treatment
For more than a century, insulin has transformed the lives of people living with diabetes. Yet despite remarkable advances in medicine, insulin remains overwhelmingly dependent on injection-based delivery.
Villya Pharmaceuticals is developing a patented oral delivery technology designed to protect insulin under harsh gastrointestinal conditions and potentially enable convenient oral administration.
Built upon Villya's proprietary platform technology and intellectual property portfolio, our approach seeks to overcome one of the greatest challenges in pharmaceutical science:
Delivering insulin orally while preserving molecular integrity.
THE VILLYA APPROACH
Protecting Insulin Before It Reaches the Bloodstream
Villya's patented platform technology is designed to create a protective molecular environment around insulin.
Our objective is to:
✅ Improve water solubility
✅ Enhance formulation stability
✅ Protect insulin under acidic gastric conditions
✅ Preserve molecular structure
✅ Support future oral delivery opportunities
The same scientific principles being applied to semaglutide are now being evaluated for insulin and other peptide therapeutics.
EARLY LABORATORY RESULTS
Testing Insulin Under Simulated Gastric Conditions
Villya is currently conducting analytical studies evaluating insulin stability under simulated gastric conditions.
Using advanced chromatographic analysis and pharmaceutical characterization techniques, our scientists are investigating whether Villya's platform can preserve insulin integrity during prolonged exposure to environments that normally destroy peptide therapeutics.
Research Objectives
• Evaluate molecular stability
• Measure structural preservation
• Assess gastric survivability
• Characterize formulation performance
• Support future development pathways
WHY AN INSULIN PILL MATTERS
WHY AN INSULIN PILL MATTERS
An effective oral insulin therapy could represent one of the most important advances in diabetes treatment in decades.
Potential future advantages may include:
✔ Greater patient convenience
✔ Reduced injection burden
✔ Improved treatment acceptance
✔ Simplified administration
✔ No refrigeration
✔ Expanded access worldwide
While significant development and regulatory milestones remain ahead, the potential impact of oral insulin continues to drive global scientific interest.
Our team that's making pharmaceuticals healther
CEO
(CHIEF EXECUTIVE OFFICER)
William Miller
Inventor of Villya's Technology
William is a visionary leader with extensive experience in international diplomacy, aerospace, and pharmaceutical innovation. He attended Indiana State University and began his distinguished career contracting at the U.S. Department of State, serving for nearly a decade on a Medevac team within the International Narcotics and Law Enforcement division across multiple U.S. Embassies overseas. This role allowed William to hone his diplomatic skills and build a robust network of international contacts.
Upon returning to the United States, William was recruited by SpaceX to contribute to the Dragon Project, playing an integral role in achieving critical milestones for the successful launch of U.S.-manufactured spacecraft with astronauts on board.
In his entrepreneurial journey, William founded S7LLC, a medical device company focused on importing and licensing rapid diagnostic tests for Schistosomiasis and COVID-19. He later transformed S7LLC into ICT International, where, as President, he expanded the company's offerings to 13 different rapid diagnostic tests for infectious diseases globally.
In his pursuit of innovation in the pharmaceutical industry, William founded Villya Pharmaceuticals, where he created and patented a groundbreaking drug to treat Female Genital Schistosomiasis (FGS) (approval US 10,857,151 B1). His achievements include the development of Liquid Praziquantel, a patent-pending formulation that makes the drug accessible for children by enhancing its solubility and bioavailability through Villya's patented carbohydrate loading technology. Villya has since patented 483 life-saving drugs, transforming them into water-soluble aggregates that are easily absorbed.
A pioneer of excellence, William played a crucial role in securing the U.S. patent office's approval for Erectile Dysfunction Therapeutics (US 12,115,222 B2) on October 15, 2024, covering five second-generation ED medications. In early 2024, he divested Villya’s intellectual property related to supplements and CBD patents to form Hythlayn Inc., which now boasts over 382 improved water-soluble supplements, including the CBD family.
William is the ideal leader for Villya Pharmaceuticals'future, with his unparalleled international connections, diplomacy skills, and a remarkable track record of managing government and private projects worth over $700 million.
CSO
(CHIEF SCIENTIFIC OFFICER)
Sreeshailam Aare
Ph.D Organic Chemistrey
